LLY Earnings
2026-04-30
EPS Estimate
$7.20
$3.63 – $8.16
Revenue Estimate
$17.6B
Earnings Trend
beating
Current Price
$935.58
Our Position
bullish · highEli Lilly's $7.8B deal and FDA boost growth
structured data
est. revisions falling
(-1.6pp / 30d)
The combination of blockbuster diabetes drugs, strategic acquisitions, and AI partnerships accelerates Lilly's transition into a biotech powerhouse with sustained revenue and innovation growth.
Watch: Track early sales of Foundayo and Centessa integration progress to gauge new revenue streams and pipeline expansion.
Data Signal Summary
2 bullish
2 bearish
Insider buying cluster
Put/call 0.5 (bullish skew)
Analysts: bearish
Price downtrend
Key Context
Analyst Consensus
bearish
Insider Activity
selling
Price Trend
downtrend
1-Month Return
-6.8%
From 52w High
-15.6%
P/E Ratio
40.8
Est. Revisions (30d)
-0.7% 2up/1dn
Analyst Target (mean)
$1209 $850–$1500
Options P/C Ratio
0.48 1C/2P unusual
Est. Dispersion
63% 19 analysts
Insider Cluster
strong buy (officer)
Fund Convergence
strong D.E. Shaw, Citadel, Renaissance, Bridgewater, Soros
Recent Activity
insider trade
Stock Award(Grant) at price 818.02 per share.
insider trade
Stock Award(Grant) at price 1036.05 per share.
insider trade
Stock Award(Grant) at price 1036.05 per share.
insider trade
Stock Award(Grant) at price 1036.05 per share.
insider trade
Stock Award(Grant) at price 1036.05 per share.
insider trade
insider trade
insider trade
insider trade
insider trade
Stock Award(Grant) at price 1044.67 per share.
Get alerted when this prediction scores after earnings.
